Charting a course for optimal value and access
Founded in 1994, Compass Strategic Consulting is an evidence-based value and access strategy company specializing in pricing and reimbursement solutions for drugs, diagnostics, and devices in US and global markets.
Compass executes about fifty to sixty projects a year across a wide range of therapeutic categories reflective of current clinical research investment. In the last few years, metabolism, oncology and neurology have led the rankings of projects by therapeutic category. Cutting across all therapeutic categories are rare diseases where Compass has developed over thirty-five clinical and market access assessments in the last three years.
Current clients include top ten global pharmaceutical, biotech, medical device and diagnostic companies, emerging life science companies, and venture funds. We have an extensive global network and capabilities and have access to Yale University resources and talent.
Compass delivers insightful results and meets tight deal deadlines. We have a 22 year track record of delivering projects and results on time and within budget.
LASER and Compass Strategic Consulting Form Strategic Alliance to Offer Enhanced Market Access Services to the Biopharma Industry
May 10, 2016 – LASER and Compass have entered into a strategic alliance in order to offer clients an integrated and full service strategic and tactical market access offering across the product life-cycle. Collectively the alliance brings decades of commercial experience backed by industry leading scientific credentials to help its customers navigate the increasingly challenging market access environment for new and existing health innovations.
Industry sectors we service include:
- Medical device and diagnostic
- Ex-US pharma/biotech
- Emerging life science
- Venture funds